Last reviewed · How we verify

OCTAPLAS

University College, London · FDA-approved active Small molecule Quality 5/100

OCTAPLAS is a Small molecule drug developed by University College, London. It is currently FDA-approved. Also known as: plasma exchange, octaplas.

At a glance

Generic nameOCTAPLAS
Also known asplasma exchange, octaplas
SponsorUniversity College, London
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about OCTAPLAS

What is OCTAPLAS?

OCTAPLAS is a Small molecule drug developed by University College, London.

Who makes OCTAPLAS?

OCTAPLAS is developed and marketed by University College, London (see full University College, London pipeline at /company/university-college-london).

Is OCTAPLAS also known as anything else?

OCTAPLAS is also known as plasma exchange, octaplas.

What development phase is OCTAPLAS in?

OCTAPLAS is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing